Q4 2024 EPS Estimates for Bristol-Myers Squibb (NYSE:BMY) Increased by Analyst

• 3 High-Yield Dividend Stocks for Income Now and Growth Later

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at Zacks Research increased their Q4 2024 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research report issued to clients and investors on Wednesday, June 26th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will earn $1.70 per share for the quarter, up from their prior estimate of $1.69. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $0.58 per share. Zacks Research also issued estimates for Bristol-Myers Squibb's FY2026 earnings at $6.25 EPS.

BMY has been the topic of a number of other reports. StockNews.com downgraded Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Thursday. Barclays dropped their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating on the stock in a report on Friday, April 26th. Societe Generale downgraded Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research note on Monday, March 11th. BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating for the company in a research report on Friday, April 26th. Finally, Wells Fargo & Company raised their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 18th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $60.00.

• Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore

Read Our Latest Report on Bristol-Myers Squibb

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $41.53 on Monday. The firm has a market cap of $84.19 billion, a P/E ratio of -13.40, a PEG ratio of 14.21 and a beta of 0.43. Bristol-Myers Squibb has a twelve month low of $39.63 and a twelve month high of $65.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a 50 day moving average of $42.97 and a 200 day moving average of $48.11.

• Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The company's revenue for the quarter was up 4.7% compared to the same quarter last year.

Institutional Investors Weigh In On Bristol-Myers Squibb

Hedge funds have recently made changes to their positions in the company. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $27,000. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. Accordant Advisory Group Inc bought a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at approximately $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter worth about $34,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the 4th quarter valued at $40,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.78%. Bristol-Myers Squibb's payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

• Five stocks we like better than Bristol-Myers Squibb
• Market Cap Calculator: How to Calculate Market Cap
• Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
• Using the MarketBeat Dividend Yield Calculator
• What's Behind Walgreens Stock Plunge: What Investors Can Do Next
• Procter & Gamble NYSE: PG Pulls Back After Shaky Guidance
• MarketBeat Week in Review – 6/24 - 6/28

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Trump’s arrest is phase one (From Porter & Company) (Ad)

Should you invest $1,000 in Bristol-Myers Squibb right now?

Before you consider Bristol-Myers Squibb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.

While Bristol-Myers Squibb currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here